Aeglea BioTherapeutics Debt to Equity

Aeglea BioTherapeutics (AGLE) currently reports a debt-to-equity ratio of 0.0. That is below the Healthcare sector average of 0.31. Use the charts on this page to explore Aeglea BioTherapeutics's debt-to-equity ratio history and peer comparisons.

Aeglea BioTherapeutics's debt-to-equity ratio of 0.0 is lower than the Healthcare sector average of 0.31. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Aeglea BioTherapeutics's market price to a fundamental measure such as earnings, sales, or book value. At 0.0, AGLE can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 0.0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.31. From there, open related valuation or income-statement pages for Aeglea BioTherapeutics, and consider following AGLE for alerts when major investors trade the stock.

Aeglea BioTherapeutics is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows 0.0 versus a sector average near 0.31. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AGLE with unrelated industries.